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Summary In order to optimize the therapeutic index of combining etoposide, epirubicin, cisplatin, 5-fluorouracil (5-FU), leucovorin (EEPFL)
chemotherapy in the treatment of advanced gastric cancer, a trial of a novel schedule ofweekly administration was conducted. Weekly EEPFL
treatment consisted of a concomitant boost of etoposide 40 mg m-2 i.v. over 30 min, epirubicin 10 mg m-2 i.v. over 5 min to a backbone
regimen, weekly PFL chemotherapy with cisplatin 25 mg m-2, 5-FU 2200 mg m-2, leucovorin 120 mg m-2 given simultaneously by 24-h i.v.
infusion. Response, survival and toxicity were evaluated. Forty-two patients were studied. Median age was 69 (range 31-84) years. Twenty-
six per cent of patients showed complete response and 45% partial response. The overall response rate was 71% (95% confidence interval
58-84%). For a total of 507 weekly EEPFL cycles delivered, the incidence of grade 4 leucopenia was 1% of cycles. One patient died of
neutropenia septicaemia. There was no other grade 4 toxicity. Grade 3 and 2 leucopenia occurred in 7% and 14% of cycles. The incidence of
grade 3 and 2 mucositis was 1% and 3% of cycles. Grade 3 and 2 diarrhoea occurred in 0.4% and 1.6% of cycles. Overall median survival was
10 months (range 3-41+ months). Weekly EEPFL chemotherapy is an effective regimen with tolerable toxicities in the treatment of advanced
gastric cancer. A randomized controlled clinical trial to formally assess the efficacy and benefit of EEPFL chemotherapy is under way.
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Gastric cancer is one of the most common cancers in the world.
Only 40% ofpatients are amenable to potentially curative surgery
(Ajani et al, 1995). Post-operative gastric cancer adjuvant strate-
gies have not yet been decisively successful in improving overall
survival (Kelsen, 1996). Gastric cancer is the most chemosensitive
cancer ofthe gastrointestinal tract. Response rates from 8% to 30%
from single-agent chemotherapy have been reported (Alexander
et al, 1997). Although higher response rates were reported using
combination chemotherapy, randomized controlled clinical studies
showed no survival benefits when combination chemotherapy was
compared with single agent (Kim et al, 1993; Cullinan et al, 1994).
Randomized clinical trials also failed to show survival benefit from
various combination chemotherapy regimens (Cocconi et al, 1994;
Wilke et al, 1995). Only a few trials have reported results that indi-
cate survival, palliative or cost benefit for patients treated with
chemotherapy (Glimelius et al, 1995, 1997). Therefore, new effec-
tive and tolerable chemotherapy is urgently needed for the treat-
ment ofadvanced gastric cancer patients.
5-Fluorouracil (5-FU) represents the most extensively studied
single agent. Various schedules and dose intensities of 5-FU have
been studied, and response rates ofabout 20% have been reported
(Gohmann et al, 1989). Various methods to potentiate 5-FU anti-
cancer activity have been tried in gastric cancer patients.
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Biochemical modulation of 5-FU (F) by methotrexate or leuco-
vorin (L) has been found to enhance 5-FU-induced cytotoxicity
(Cadman et al, 1979; Keyomarsi and Morar, 1988). The combina-
tion of 5-FU, doxorubicin (adriamycin), methotrexate (FAMTX)
and FL has resulted in 29-59% response rates (Klein et al, 1983;
Berenberg et al, 1995). Cisplatin and 5-FU (PF) are synergistic in
vitro (Schabel et al, 1979), and PF chemotherapy has resulted in a
51% response in advanced gastric cancer patients (Kim et al,
1993). Etoposide and epirubicin are regarded as being active
agents for the treatment of gastric cancers and have been inte-
grated into many combination chemotherapy regimens (Wilke et
al, 1990; Findlay et al, 1994; Zaniboni et al, 1995). The combina-
tion of cisplatin and a 21-day infusion of 5-FU and leucovorin
(PFL) has produced a 48% response rate (Leichman et al, 1994).
We found that 96-h infusional PFL chemotherapy every 3 weeks
also produced anti-cancer activity in refractory gastric cancer, with
a 27% response rate (Lin et al, 1994).
In an attempt to further potentiate the therapeutic effect of PFL
chemotherapy in gastric cancer, we added two more active drugs,
etoposide and epirubicin, into our 3-weekly PFL chemotherapy
regimen (Chi et al, 1994). A pilot study of combining etoposide,
epirubicin, cisplatin, 5-FU and leucovorin chemotherapy (EEPFL)
given every 3 weeks was performed. Encouraging anti-cancer
activity but excessive grade 4 neutropenia and grade 3 mucositis
were observed. We then performed a second pilot study of weekly
EEPFL chemotherapy in gastric cancer using the same drugs and
dose intensity of E, E, P and L but changing the chemotherapy
schedule from 96 h infusion every 3 weeks to 24 h infusion weekly,
based on our previous experience that PFL chemotherapy dose-
limiting toxicity can be eliminated, anti-cancer effect maintained
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and the dose intensity of5-FU doubledby using aweekly 24-h PFL
infusional schedule (Chi etal, 1995). The results ofour secondpilot
study indicated that changing schedule from every 3 weeks to
weekly may result in a high therapeutic index. We therefore
performed this phase II clinical trial to further investigate the effi-
cacy ofweekly EEPFL chemotherapy in the treatment ofadvanced
gastric cancer patients.
PATIENTS AND METHODS
Patient selection
Patients with histologically proven gastric adenocarcinoma with
primarily unresectable, locally recurrent after gastrectomy or
metastatic diseases were eligible. All patients had no prior
chemotherapy. Bidimensionally measurable disease was manda-
tory even for patients with locally advanced disease. Eastern
Cooperative Oncology Group (ECOG) performance status (PS) of
3 or better, adequate bone marrow function (leucocyte count
> 4000 ul-', platelet count > 100 000 ul-'), renal function (serum
creatinine < 1.6 mg dl-'), cardiac function (ejection fraction
> 45%) and liver function (bilirubin < 2 mg dl-') were required.
All patients gave informed consent. The protocols have been
carried out with ethical committee approval.
Treatment plan
Weekly EEPFL treatment consisted of weekly etoposide
40 mg m-2 i.v. over 30 min, weekly epirubicin 10 mg m-2 i.v. over
5 min and cisplatin 25 mg m-2, 5-FU 2200 mg m-2, leucovorin 120
mg m-2 given simultaneously by weekly 24-h i.v. infusion. (Chi et
al, 1994). The chemotherapy can be given as an outpatient
regimen with a portable infusion pump (Baxter HealthCare,
Deerfield, IL, USA) through implanted central venous access.
Dose modifications were based on the degree of leucopenia and
thrombocytopenia as determined on day 1 of each weekly cycle
immediately before chemotherapy. Full-dose EEPFL chemo-
therapy would be delivered if WBC was > 2500 ul-' and platelet
> 75 000 ul-'. Etoposide and epirubicin were omitted for WBC
between 2000 and 2500 ul-'. Weekly EEPFL would be delayed at
least 1 week for WBC < 2000 ul-' or grade 2-4 mucositis or diar-
rhoea. Patients would be taken off study if treatment delay was
more than 3 weeks. Cisplatin was not given for serum creatinine
> 2 mg ml-'. Etoposide and epirubicin were reduced 25% or 50%
for grade 3 or grade 4 neutropenia nadir during chemotherapy. 5-
FU was reduced 10% or 20% for grade 2 or 3 mucositis/diarrhoea
during chemotherapy. Weekly EEPFL chemotherapy would be
discontinued when disease progression, intolerance to therapy or a
stable disease after an 8-weekly cycle oftherapy was encountered.
Generally, another 6-weekly cycle of therapy would be given
whenever a complete or partial response was first achieved.
Response and toxicity criteria
Evaluation procedures, including physical examination,
gastroscopy and biopsy, complete blood count, blood chemistry,
tumour markers (CEA, CA-199, CA-125), chest radiography,
computerized tomography scan ofthe abdomen and sonography of
the abdomen, were performed before chemotherapy. Complete
blood counts were performed weekly and blood chemistry every 3
weeks. Physical measurable tumour and treatment toxicity were
Table 1 Patient characteristics
Age (years)
Median (range)
Sex
Male/female
Performance status
0-1
2
3
Post-gastrectomy
Locally recurrent
Metastatic
Non-resectable
Locally advanced
Metastatic
Sites of disease
Stomach
Liver
Intra-abdominal lymph node
Supraclavicular lymph node
Lung
Pelvic mass
Ascites
Skin
Tumour markers
69 (31-84)
37/5
23
11
8
3
20
9
10
12
19
13
3
4
4
3
1
34
Table 2 Response
Patients %
CR 11 26
PR 19 45
SD 6 14
PD 4 10
Not evaluable 2 5
Total 42 100
evaluated weekly before each treatment. Tumour markers, organ
imaging and other radiological studies were performed every 1 or
2 months. Complete response (CR) was defined as disappearance
of all clinical evidence of disease with normalization of tumour
markers. Partial response (PR) was defined as diminution of.50%
reduction in the sum ofproducts ofthe perpendicular diameters of
all the initial measurable masses for at least 4 weeks. Progressive
disease (PD) was defined as a 25% increase in the products of
measurable diameters, or the development of a new lesion. Stable
disease (SD) was any measurement not fulfilling the criteria for
response or progression.
Statistical methods
The Simon two-stage phase II clinical trial design was used
(Simon, 1989), with 23 patients in the first stage and 39 patients in
the second stage. If the response rate was less than 11 out of 23
patients in the first stage or 23 out of 39 patients in the second
stage, the treatment would be rejected, with a response rate of50%
or 70%, respectively, with a of 0.1 and e of 0.1. Response rates
were compared using Fisher's exact test. Survival was calculated
using the Kaplan and Meier method (Kaplan and Meier, 1958).
The time to progression was measured from the time offirst-study
drug administration to documented progressive disease.
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RESULTS
Between August 1992 and November 1995, 42 patients were
studied. Forty patients were evaluable for response. One patient
was lost to follow-up after two cycles of therapy. One patient had
inadequate infusion time for the first cycle of therapy and did not
return for the second cycle of therapy. Patient characteristics are
listed in Table 1. There were 37 male and five female patients. The
median age was 69 years. There were 34 patients with ECOG PS
0-2 and eight patients with grade 3 PS. Nineteen patients were
inoperable because of locally advanced disease or metastatic
disease. Twenty-three patients had previous gastrectomy for
gastric cancer and presented with local recurrence or metastasis.
No patient had previous chemotherapy.
Response and survival
The median cycles of weekly EEPFL chemotherapy given was 12
(range 1-30). The response rates are summarized in Table 2. There
were 26% CR and 45% PR observed. The overall response rate
(CR + PR) was 71% (confidence interval 58-84%). Three clinical
CR patients (one local disease and two metastasis) had laparotomy
after weekly EEPFL chemotherapy, and all had pathological CR.
There were 14% SD and 10% PD. The overall response rate was
79% in patients with ECOG PS 0-2 and 37.5% in patients with
ECOG PS 3, this being statistically significant (P = 0.03). There
was no statistically significant difference in response rates
between patients with local disease vs metastasis, gastrectomy vs
no gastrectomy, young vs old age (. 60 years), sites ofmetastasis,
< 3 vs . 3 tumour sites or ascites.
Relief from disease-related symptoms developed gradually, but
significantly, ifresponse to chemotherapy was achieved; in partic-
ular, relieffrom various pain and epigastric fullness sensations was
noted. The performance status was improved in 53% of patients
who had original PS of2-3 and maintained in 83% ofpatients who
had original PS of 0-1. The median time to CR was 12 weeks
(range 8-16 weeks). The median time to PR was 8 weeks (range
3-16 weeks). The median response duration ofCR was 15 months
(range 6-34 months). The median duration of PR was 5 months
(range 2-18 months). The survival rates for all and different groups
ofpatients treated with weekly EEPFL chemotherapy are shown in
Figures 1 and 2. The overall median survival was 10 months (range
3-41 months). The median survival of the CR patients was 27
months (range 6-41+ months). The median survival ofPR patients
was 15 months (range 3-24 months). The median survival times
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Figure 1 Survival of patients treated with the weekly EEPFL chemotherapy
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Figure 2 Survival of localized or metastatic gastric cancer patients treated
with weekly EEPFL chemotherapy
for patients with localized disease and metastatic disease were 18
and 9.5 months respectively (P = 0.9). The median progression-
free survival times forpatients with localized ormetastatic diseases
were both 5 months. Three patients in this study remained disease
free and alive at 24+, 26+ and 34+ months.
Table 3 Percentage toxicity from weekly EEPFL chemotherapy
Per cycle analysis (n = 507) Per patient analysis (n = 42)
Grade (%) Grade (%)
Toxicity 1 2 3 4 1 2 3 4
Leucopenia 18 14 7 1 12 24 48 9.5
Thrombocytopenia 6 3 1 0 17 9.5 7 0
Anaemia 35 30 5 0 7 36 45 0
Nausea/vomiting 53 10 2 0 48 12 9.5 0
Mucositis 8 3 1 0 36 24 9.5 0
Diarrhoea 2 1.6 0.4 0 24 17 5 0
Nephrotoxicity 0.6 0.4 0 0 7 5 0 0
Neurotoxicity 1 0 0 0 5 0 0 0
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Toxicity
The toxicity of 507 cycles of weekly EEPFL chemotherapy in 42
patients is shown in Table 3. The main toxicity was haematological.
Grade 4 leucopenia was documented in 1% of courses and 9.5% of
patients; there was no other grade 4 toxicity. Grade 3 leucopenia
occurred in 7% of courses and 48% of patients. In 2% of courses,
leucopenic fever episodes were documented, and one patient died
of leucopenic sepsis. Grade 3 anaemia occurred in 45% of patients
and packed red blood cell transfusions were given. The median
drop in haemoglobin level was 3.5 mg %. Grade 3 nausea and
vomiting occurred in 2% of courses and 9.5% of patients. In 24%
and 9.5% of patients, grade 2 and 3 mucositis was experienced, as
well as in 3% and 1% of cycles respectively. Grade 2 and 3 diar-
rhoea were noted in 17% and 5% ofpatients and in 1.6% and 0.4%
of cycles. Skin hyperpigmentation was noted in 64% of patients,
and hand-foot syndrome was experienced in 9.5%. Central venous
catheter occlusions occurred in four, infection in one and line
removal in three patients. Other toxicities were mild and tolerable.
Sixty-nine per cent of patients needed dose modification after a
median of 5 weeks of therapy. The median duration of each treat-
ment delay for toxicity recovery was 1 week (range 1-3 weeks). In
this study, the clinical benefit on palliating symptoms and improved
performance status was not negated by the frequent and short
interval ofthe treatment cycle because ofthe well-tolerated toxicity
profile and the very short duration of toxicity.
DISCUSSION
The results of this phase II study indicate that weekly EEPFL is a
highly effective chemotherapy for the treatment of advanced gastric
cancer. The overall response rate of 71% and CR of 26% from this
phase II study is encouraging compared with published data. Wils
(1996) proposed that there have been three generations in the devel-
opment of combination chemotherapy treatment for gastric cancer
in the past 2 decades. FAM [5-FU, doxorubicin (adriamycin), mito-
mycin C] is regarded as being 'first-generation' chemotherapy and
was commonly used in the early 1980s. FAMTX and EAP [etopo-
side, doxorubicin (adriamycin), cisplatin] are examples of second-
generation chemotherapy, also commonly used in the late 1980s,
and appeared to be more active than first-generation regimens, such
as FAM, with overall response rates of 33-41% from randomized
clinical trials (Wils et al, 1991; Kelsen et al, 1992). Combination
chemotherapy, such as PF, ECF (epirubicin, cisplatin, 5-FU), ELF
(etoposide, 5-FU, leucovorin) and PELF (cisplatin, epirubicin,
leucovorin, 5-FU), designed based on protracted infusional 5-FU or
on a 5-FU/leucovorin combination, has had response rates ofaround
50% and represents the major trend of combination chemotherapy
developed in the early 1990s for advanced gastric cancer (Kim et al,
1993; Cocconi et al, 1994; Findlay et al, 1994; Zaniboni et al, 1995;
Wils et al, 1996). However, a randomized trial from EORTC
comparing FAMTX and ELF with PF failed to show the superiority
of different second-generation regimens (Wilke et al, 1995). There
is a need for the development of a newer generation of
chemotherapy regimens for advanced gastric cancer.
High-dose infusional 5-FU/leucovorin (HDFL) combination
chemotherapy may become the basis of 'third-generation'
chemotherapy for the treatment of gastric cancer (Wils, 1996).
Vanhoefer et al (1994) first reported the efficacy of weekly HDFL
chemotherapy, with an 18% response rate in patients who had
previous chemotherapy. They reported a 67% response rate (7%
CR, 60% PR) by adding bi-weekly cisplatin to weekly HDFL
chemotherapy in advanced gastric cancer (Vanhoefer et al, 1995).
Yeh et al (1997) recently reported a response rate of 48% by
weekly HDFL chemotherapy in advanced gastric cancer patients
with poor performance status. The response rate increased to 72%
(23% CR, 49% PR) by adding 3-weekly cisplatin and etoposide to
weekly HDFL chemotherapy (Cheng et al, 1996). Our weekly
EEPFL chemotherapy is one of the most effective 'third-genera-
tion' chemotherapy regimens and involves adding weekly epiru-
bicin, etoposide and cisplatin to weekly HDFL chemotherapy.
The median survival of advanced gastric cancer patients from
most randomized clinical trials ranges from 6 to 10 months.
Although the median survival of 10 months in this study appears to
be similar to others, we should take into account that the median
age of our patients was 69 years and many patients in this study had
poor performance. We are encouraged that there are three patients
who remain to be disease free 24-34 months after chemotherapy.
The median survival of 27 months in CR patients is very encour-
aging, especially as eight out of 11 CR patients had metastatic
disease and as the median survival of patients with gastric cancer
even after curative resection is only 24 months (Diehl et al, 1983).
Weekly EEPFL chemotherapy has a relatively high response
rate and CR rate, with good tolerability. It should be considered for
future adjuvant chemotherapy in gastric cancer after resection.
Weekly EEPFL should also be considered for neoadjuvant
chemotherapy for tumour reduction in local advanced gastric
cancer and to increase the resection rate. Four patients with locally
advanced gastric cancer who had weekly EEPFL and subsequent
radiotherapy to the tumour bed area had a median survival of 24
months (range 16-27 months). Although the number of patients in
this study is too small to draw any conclusions, combined
chemotherapy and radiotherapy may be a feasible and effective
approach in the management of local advanced gastric cancer,
with possible long-term survival (Moertel et al, 1994).
This weekly EEPFL was developed from a weekly PFL back-
bone regimen (Chi et al, 1995). Whether the optimal schedule
of addition of other active drugs to the weekly backbone
chemotherapy should be weekly or every 3 weeks is uncertain.
The addition of a frequent small-dose schedule of chemotherapy
along with the backbone regimen may be analogous to a
'concomitant boost' in radiotherapy (Peters et al, 1988). The effect
of a concomitant boost may reduce the chance oftumour repopula-
tion, reduce the repair ability and therefore increase efficacy ofthe
weekly PFL chemotherapy. Whether the chemotherapy situation is
comparable to radiotherapy is unknown, but the inclusion of
etoposide and epirubicin in a weekly schedule in this weekly
EEPFL chemotherapy appears to give an encouraging response
rate. Using a weekly schedule, it is easier to monitor treatment and
adjust dose so that only grade 1 or 2 toxicity appears than it is
using a 3-weekly schedule. The true value of this approach
remains uncertain and awaits further clinical investigation.
In conclusion, this weekly EEPFL is a new, well-tolerated and
highly effective chemotherapy in the treatment ofadvanced gastric
cancer. A randomized study comparing weekly EEPFL, weekly
high-dose FL and standard bolus 5-FU chemotherapy on advanced
gastric cancers is currently being undertaken in our institution.
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